



**NEVADA  
HEALTH  
RESPONSE**

**FOR IMMEDIATE RELEASE**

December 30, 2020

Meghin Delaney

Communications Director

CONTACT: [pressroom@nvhealthresponse.nv.gov](mailto:pressroom@nvhealthresponse.nv.gov)

**COVID-19 Press Bulletin for 12-30-2020**

Carson City, NV — Today, Julia Peek, Deputy Administrator of Community Health Services, was joined by Dr. Mark Pandori, Nevada's Chief of Testing, to provide updates on Nevada's ongoing COVID-19 response, testing and reporting during a teleconference with members of the media.

This bulletin provides facts, figures, and informational items from the call. As a reminder, data is provided in a dashboard on the home page of the [Nevada Health Response](https://www.nvhealthresponse.nv.gov) website and can be accessed 24 hours a day.

There will be no media call on Friday, Jan. 1. The next call will be Monday, Jan. 4, 2021.

**SUMMARY:**

- As of today, Nevada has logged 222,594 cases, with the 14-day rolling average of daily cases being 1,654.
- Nevada has now completed a total of 2,068,519 molecular tests since the beginning of COVID-19.
- The test positivity rate over the last 14 days is 20.1%.
- There are currently 1,988 COVID-19 hospitalizations (1,830 confirmed; 158 suspected)

- More information on hospitalization trends can be found on the [Nevada Hospital Association](#) website.
- Since COVID began in the state, to today, a total of 45,111 cases have been identified as a result of contact tracing efforts statewide. This represents 20.3% of the cases reported to date.
- There have been a total of 314,626 downloads of the COVID Trace app, as of last night.
  - 153 cases had the app at the time of their diagnosis with 97 related exposure notifications sent as a result of those cases.

Dr. Mark Pandori, Nevada's Chief of Testing, provided an update from the State Public Health Laboratory.

- Nevada will begin utilizing new equipment and additional staff have been trained for the new year. This will allow for larger testing capacities.
- Preliminary data suggests that while the B117 variant may spread and infect more readily, it appears to not cause more severe illness. Secondly, the efficacy of the COVID-19 vaccine is not expected to be compromised.
  - Newly acquired equipment for genetic surveillance will allow for real time rapid sequencing methods.

###